ArticleBlood advances2017

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.

Jay Y Spiegel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.